Premium
Developing a Blood Test to Support Treatment of Surgically Induced Type I Diabetes
Author(s) -
Dailey Allyson,
Kanak Mazhar,
Couch Robin
Publication year - 2020
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2020.34.s1.09338
Subject(s) - autotransplantation , islet , medicine , insulin , metabolite , transplantation , diabetes mellitus , surgery , endocrinology
In this pilot‐scale investigation, serum was collected from nine study participants, each of which having underwent a procedure of total pancreatectomy with islet autotransplantation. The procedure was a success with 6 of the patients (i.e. they are not dependent on insulin injections), whereas the insulin‐producing islet cells did not successfully autotransplant in 3 of the patients (and thus they are dependent on insulin injections). Each of the nine patients have provided four serum samples; one obtained prior to surgery, one immediately following surgery, one 1 hr following islet autotransplantation, and one 7 days following islet autotransplantation. Following organic extraction, the serum extracts were analyzed for metabolite content using liquid chromatography quadrupole time of flight mass spectrometry (LC‐QToF). A differential comparison of the serum metabolites present in each of the samples was used to define molecular features that may serve as biomarkers of patient outcome. Subsequent tandem mass spectrometry (LC‐MS/MS), along with comparison to molecular libraries and purchased authentic standards, will identify the molecular features, and permit an assessment of their suitability for use in a predictive diagnostic test to determine patient suitability/compatibility with islet autotransplantation. Support or Funding Information 4‐VA Funds